US Stem Cell Inc - ESG Rating & Company Profile powered by AI
Full ESG analysis of US Stem Cell Inc are reached by signing up for free. This SDG assessment for US Stem Cell Inc represents the company's reporting of the UN Sustainable Development Goals. This analysis of US Stem Cell Inc employs intelligence from across the internet as well as from public filings by US Stem Cell Inc.
US Stem Cell Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 2.7; made up of an environmental score of 0.0, social score of 2.7 and governance score of 5.3.
2.7
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1393 | Vaccinex Inc | 2.8 | Medium |
| 1393 | YSP Southeast Asia Holding Bhd | 2.8 | Medium |
| 1437 | US Stem Cell Inc | 2.7 | Medium |
| 1437 | CanadaBis Capital Inc | 2.7 | Medium |
| 1437 | Cannabics Pharmaceuticals Inc | 2.7 | Medium |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does US Stem Cell Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes US Stem Cell Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes US Stem Cell Inc report the average age of the workforce?
Sign up for free to unlockDoes US Stem Cell Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes US Stem Cell Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes US Stem Cell Inc disclose cybersecurity risks?
Sign up for free to unlockDoes US Stem Cell Inc offer flexible work?
Sign up for free to unlockDoes US Stem Cell Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes US Stem Cell Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes US Stem Cell Inc conduct supply chain audits?
Sign up for free to unlockDoes US Stem Cell Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes US Stem Cell Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes US Stem Cell Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes US Stem Cell Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes US Stem Cell Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes US Stem Cell Inc disclose water use targets?
Sign up for free to unlockDoes US Stem Cell Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid US Stem Cell Inc have a product recall in the last two years?
Sign up for free to unlockDoes US Stem Cell Inc disclose incidents of discrimination?
Sign up for free to unlockDoes US Stem Cell Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas US Stem Cell Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes US Stem Cell Inc disclose parental leave metrics?
Sign up for free to unlockDoes US Stem Cell Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes US Stem Cell Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes US Stem Cell Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes US Stem Cell Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes US Stem Cell Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes US Stem Cell Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs US Stem Cell Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes US Stem Cell Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes US Stem Cell Inc disclose its waste policy?
Sign up for free to unlockDoes US Stem Cell Inc report according to TCFD requirements?
Sign up for free to unlockDoes US Stem Cell Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes US Stem Cell Inc disclose energy use targets?
Sign up for free to unlockDoes US Stem Cell Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes US Stem Cell Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for US Stem Cell Inc
These potential risks are based on the size, segment and geographies of the company.
U.S. Stem Cell, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States. Its lead product candidates include MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells or cells from a patient's body for enhancing cardiac function in chronic heart failure patients; and AdipoCell, a patient-derived cell therapy for the treatment of acute myocardial infarction, chronic heart ischemia, and lower limb ischemia. The company's product development pipeline includes MyoCell SDF-1, an autologous muscle-derived cellular therapy for improving cardiac function in chronic heart failure patients. It is also developing MyoCath, a deflecting tip needle injection catheter that is used to inject cells into cardiac tissue in therapeutic procedures to treat chronic heart ischemia and congestive heart failure. In addition, the company provides physician and patient based regenerative medicine/cell therapy training, cell collection, and cell storage services; and cell collection and treatment kits for humans and animals, as well operates a cell therapy clinic. The company was formerly known as Bioheart, Inc. and changed its name to U.S. Stem Cell, Inc. in October 2015. U.S. Stem Cell, Inc. was incorporated in 1999 and is headquartered in Sunrise, Florida.